更新SEIOMM的骨质疏松症管理指南：阿瓦洛帕病

IF 1.7 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Revista clinica espanola Pub Date : 2025-10-01 DOI:10.1016/j.rce.2025.502338

J.A. Riancho , M. Martín Millán , P. Peris , G. Martínez , en nombre de la Comisión de Redacción de las Guías de Osteoporosis de la SEIOMM

{"title":"更新SEIOMM的骨质疏松症管理指南：阿瓦洛帕病","authors":"J.A. Riancho , M. Martín Millán , P. Peris , G. Martínez , en nombre de la Comisión de Redacción de las Guías de Osteoporosis de la SEIOMM","doi":"10.1016/j.rce.2025.502338","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Osteoporosis is a highly prevalent condition. SEIOMM has published guidelines for managing these patients in 2022. The recent introduction of a new drug in Europe, abaloparatide, makes it advisable to consider its role among therapeutic options.</div></div><div><h3>Objective and results</h3><div>This article summarizes the existing information on the efficacy and safety of abaloparatide and it updates the therapeutic algorithms proposed in the guidelines.</div></div><div><h3>Conclusion</h3><div>Abaloparatide is an osteoanabolic drug with efficacy and safety similar to teriparatide. It represents a new option for treating patients with severe osteoporosis and a very high risk of fracture.</div></div>","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502338"},"PeriodicalIF":1.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Actualización de las guías de manejo de la osteoporosis de la SEIOMM: abaloparatida\",\"authors\":\"J.A. Riancho , M. Martín Millán , P. Peris , G. Martínez , en nombre de la Comisión de Redacción de las Guías de Osteoporosis de la SEIOMM\",\"doi\":\"10.1016/j.rce.2025.502338\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Osteoporosis is a highly prevalent condition. SEIOMM has published guidelines for managing these patients in 2022. The recent introduction of a new drug in Europe, abaloparatide, makes it advisable to consider its role among therapeutic options.</div></div><div><h3>Objective and results</h3><div>This article summarizes the existing information on the efficacy and safety of abaloparatide and it updates the therapeutic algorithms proposed in the guidelines.</div></div><div><h3>Conclusion</h3><div>Abaloparatide is an osteoanabolic drug with efficacy and safety similar to teriparatide. It represents a new option for treating patients with severe osteoporosis and a very high risk of fracture.</div></div>\",\"PeriodicalId\":21223,\"journal\":{\"name\":\"Revista clinica espanola\",\"volume\":\"225 8\",\"pages\":\"Article 502338\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista clinica espanola\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0014256525001018\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista clinica espanola","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014256525001018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

骨质疏松症是一种非常普遍的疾病。SEIOMM已于2022年发布了管理这些患者的指南。最近在欧洲引进的一种新药，abaloparatide，使得考虑其在治疗方案中的作用是可取的。目的与结果本文总结了阿巴洛肽的有效性和安全性的现有信息，并更新了指南中提出的治疗算法。结论阿巴巴拉肽是一种疗效和安全性与特立帕肽相当的骨合成代谢药物。它代表了治疗严重骨质疏松症和极高骨折风险患者的新选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Actualización de las guías de manejo de la osteoporosis de la SEIOMM: abaloparatida

Introduction

Osteoporosis is a highly prevalent condition. SEIOMM has published guidelines for managing these patients in 2022. The recent introduction of a new drug in Europe, abaloparatide, makes it advisable to consider its role among therapeutic options.

Objective and results

This article summarizes the existing information on the efficacy and safety of abaloparatide and it updates the therapeutic algorithms proposed in the guidelines.

Conclusion

Abaloparatide is an osteoanabolic drug with efficacy and safety similar to teriparatide. It represents a new option for treating patients with severe osteoporosis and a very high risk of fracture.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revista clinica espanola 医学-医学：内科

CiteScore

4.40

自引率

6.90%

发文量

审稿时长

28 days

期刊介绍： Revista Clínica Española published its first issue in 1940 and is the body of expression of the Spanish Society of Internal Medicine (SEMI). The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice. Revista Clínica Española is subject to a thorough double blind review of the received articles written in Spanish or English. Nine issues are published each year, including mostly originals, reviews and consensus documents.